Tenax Therapeutics, Inc. (TENX) Stock Price & Analysis
Tenax Therapeutics, Inc. (TENX) rose 1.80% to USD 10.73 as of June 10, 2026 at 02:33 UTC, according to Nexqual real-time market data.
TENX last closed at USD 10.54; the session ranged USD 10.25–10.99 on volume of 1,427,465 shares. Market capitalization is $284.61M, with a 52-week range of USD 5.34–18.38 (NCM). Source: Nexqual, June 10, 2026 at 02:33 UTC.
Key Statistics (as of June 10, 2026 at 02:33 UTC)
| Price | USD 10.73 |
|---|---|
| Change | ▲ 1.80% (up) |
| Previous Close | USD 10.54 |
| Open | USD 10.55 |
| Day Range | USD 10.25 – 10.99 |
| 52-Week Range | USD 5.34 – 18.38 |
| Volume | 1,427,465 shares |
| Market Cap | $284.61M |
| Exchange | NCM |
Technical Analysis (TENX)
Nexqual's technical model rates TENX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:33 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.43 (neutral) |
| vs SMA50 | Below (USD 12.99) |
| MACD | -0.58 (negative) |
Analyst Ratings (TENX)
Wall Street analysts rate TENX "Strong Buy" based on 7 analysts, with a mean price target of USD 29.71 (range USD 20–36), per Nexqual as of June 10, 2026 at 02:33 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 29.71 |
| High Target | USD 36 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (TENX)
| EPS Estimate | USD -0.37 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.35 vs est -0.4 ▲ beat |
| 2025-12-31 | USD -0.38 vs est -0.42 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -1.12 ▲ beat |
| 2025-06-30 | USD -0.27 vs est -0.45 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
Financials & Fundamentals (TENX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -51.71% |
| Current Ratio | 14.52 |
| Total Cash | $118.75M |
| Total Debt | $0 |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
Financial Health Score (TENX)
Nexqual rates Tenax Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:33 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $119M cash, no debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -52%, ROA -32.7% |
Ownership (TENX)
| Insider Ownership | +0.12% |
|---|---|
| Institutional Ownership | +75.69% |
| Shares Outstanding | 26.53M |
| Float | 10.61M |
| Short % of Float | +3.02% |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
Leadership (TENX)
Tenax Therapeutics, Inc. is led by Christopher T. Giordano (age 50), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:33 UTC.
| CEO, President & Director | Christopher T. Giordano (age 50) |
|---|---|
| Chief Medical Officer & Director | Stuart Rich (age 75) |
| Chief Financial Officer | Thomas R. Staab II (age 57) |
| Executive Vice President of Regulatory Affairs | Douglas Hay |
| Executive Vice President of Clinical Development & Strategy | So-Young Kim |
Major Backers & Investors (TENX)
Notable institutional backers of Tenax Therapeutics, Inc. include Price (T.Rowe) Associates Inc, T. Rowe Price, Janus Henderson Group PLC, according to Nexqual as of June 10, 2026 at 02:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 11.13% |
| T. Rowe Price | 9.92% |
| Janus Henderson Group PLC | 6.84% |
| Venrock Adviser, LLC | 6.32% |
| Perceptive Advisors Llc | 5.46% |
| Ikarian Capital, LLC | 3.84% |
| Stonepine Capital Management, LLC | 3.68% |
| Logos Global Management LP | 2.36% |
Source: Nexqual, June 10, 2026 at 02:33 UTC.
From Tenax Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
- It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▼ 10% |
| VTVT | vTv Therapeutics Inc. | USD 31.77 | ▼ 1.15% |
| PULM | Pulmatrix, Inc. | USD 1.38 | ▲ 3.76% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
| CFOR | OpGen, Inc. | USD 0.5 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:33 UTC. This page is informational and not investment advice.